Costs of Early Stage Alzheimer’s Disease in the United States: Cross-sectional Analysis of a Prospective Cohort Study (GERAS-US)

Manuscript Number: 


Jeffrey Scott Andrews, Valerie Bruemmer, Howard Fillit, Yongin Kim, Dorene M. Rentz, Rebecca L. Robinson, Ronald L. Schwartz, Wenyu Ye, Anthony Zagar


Jeffrey Scott Andrews

  • Equity:
    Employee and minor shareholder of Eli Lilly & Company
    Employee of Eli Lilly & Company

Valerie Bruemmer

  • Equity:
    employment compensation at Eli Lilly includes company stock
    Eli Lilly employee at time of research project

Howard Fillit

  • Consulting Fees:
    I receive consulting fees or participate on paid advisory boards from Alector, vTv, Lundbeck, Otsuka, Lilly, Biogen (RTI), Roche, Genentech, Merck, Samus, Pfizer

Yongin Kim

  • Equity:
    minor stock holder
    employed by Lilly

Dorene M. Rentz

  • Consulting Fees:
    Consulting fees with Biogen Idea Consulting fees with Digital Cognition Technologies Scientific Advisory Board with Neurotrack

Rebecca L. Robinson

  • Equity:
    Minor stockholder of Eli Lilly and Company stocks.
    Employee of Lilly Research Labs, Eli Lilly and Company

Ronald L. Schwartz

  • Nothing to Disclose

Wenyu Ye

  • Equity:
    As an Eli Lilly and Company employee and owned Eli Lilly and Company stocks
    I am a full-time employee of Eli Lilly and Company

Anthony Zagar

  • Sponsors:
    Employee of Eli Lilly and Company